Equities Analysts Offer Predictions for CVKD FY2026 Earnings

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Zacks Research dropped their FY2026 earnings per share estimates for shares of Cadrenal Therapeutics in a note issued to investors on Wednesday, April 8th. Zacks Research analyst D. Bautz now forecasts that the company will earn ($5.08) per share for the year, down from their previous estimate of ($3.00). The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($7.59) per share. Zacks Research also issued estimates for Cadrenal Therapeutics’ FY2027 earnings at ($2.93) EPS and FY2028 earnings at ($2.89) EPS.

A number of other research firms have also weighed in on CVKD. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a research note on Wednesday, January 21st. HC Wainwright reduced their target price on Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $13.00.

Cadrenal Therapeutics Stock Performance

NASDAQ:CVKD opened at $4.76 on Friday. The stock’s fifty day moving average is $6.35 and its 200 day moving average is $9.08. Cadrenal Therapeutics has a fifty-two week low of $4.21 and a fifty-two week high of $17.50. The firm has a market capitalization of $11.95 million, a PE ratio of -0.71 and a beta of 1.53.

Cadrenal Therapeutics (NASDAQ:CVKD) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.24).

Institutional Trading of Cadrenal Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its stake in Cadrenal Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after purchasing an additional 1,818 shares during the period. JPMorgan Chase & Co. bought a new position in shares of Cadrenal Therapeutics during the 3rd quarter worth $103,000. DRW Securities LLC bought a new position in shares of Cadrenal Therapeutics during the 4th quarter worth $171,000. Finally, Citadel Advisors LLC bought a new position in shares of Cadrenal Therapeutics during the 3rd quarter worth $274,000. Hedge funds and other institutional investors own 7.92% of the company’s stock.

Key Stories Impacting Cadrenal Therapeutics

Here are the key news stories impacting Cadrenal Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterates a “Buy” and a $13 price target, with modelled FY2026–FY2028 estimates that are materially less negative than the consensus—this gives investors a clear upside thesis if clinical or corporate catalysts materialize. HC Wainwright Issues Pessimistic Forecast for Cadrenal Therapeutics (NASDAQ:CVKD) Stock Price
• Positive Sentiment: Short interest fell sharply in March to ~29,406 shares (down ~60.6% vs. mid‑March), leaving a short-interest ratio of about 0.6 days and only ~1.6% of float shorted — reduces near‑term short pressure and the likelihood of large short-driven moves.
• Neutral Sentiment: April short‑interest reporting shows inconsistent/zero figures (data anomaly reported as of April 10), making April short‑interest trends unclear; treat April data cautiously until clarified.
• Negative Sentiment: Zacks Research lowered multiple forward estimates (FY2026, FY2027 and issued FY2028/FY2028 forecasts), cutting EPS outlook across quarters and years — this pushes the near‑term earnings trajectory more negative and likely pressures the stock. See company page for the Zacks notes. MarketBeat: CVKD analyst notes (Zacks)

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.